fda bpc-157 warning unapproved drug letter new BPC-157: Miracle Healing Peptide or Hidden Danger? FDA panel narrowly backs unapproved

At Bellus Touch, we provide expert care to enhance your health

Principal Display Panel - Medication Box Rx only MEDICATION BOX (Box 1 of 2) NDC 62064-381-04 4 vials EGRIFTA WRTM (tesamorelin) for injection 11.6 mg/vial For Subcutaneous Use Single-patient-use vial Sterile lyophilized powder New Formulation, Dose, Mixing Instructions, and Storage One (1) mixed EGRIFTA WR vial provides daily doses for seven (7) days EGRIFTA WR and EGRIFTA SV are not substitutable

Protocol for men starting TRT Beginning HCG when starting testosterone therapy prevents testicular atrophy before it occurs

It is not approved for human or animal consumption, diagnosis, treatment, or prevention of any condition

Who performs the injections